Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAX 40279

Next Previous
Drug Profile

MAX 40279

Alternative Names: Max 4; MAX-40279; MAX-40279-001; MAX-40279-01; Max-5; Max-6; Multi-target tyrosine kinase inhibitor - Maxinovel

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Maxinovel Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Hematopoietic progenitor kinase 1 inhibitors; Janus kinase inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer
  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Preclinical Idiopathic pulmonary fibrosis
  • No development reported Solid tumours

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in China (PO)
  • 11 Apr 2023 Maxinovel plans a phase I trial in Idiopathic pulmonary fibrosis in 2023 (Maxinovel Pharmaceuticals pipeline, April 2023)
  • 11 Apr 2023 Maxinovel plans a phase II trial in Acute myeloid leukaemia in 2023 (Maxinovel Pharmaceuticals pipeline, April 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top